Market Signal Briefing

Bitcoin.com and Concordium have teamed up to introduce age-verified stablecoin payments to 75 million wallets, blending privacy with new compliance standards.

The integration, powered by Chainlink’s NAVLink oracle technology, represents another leap in bridging traditional finance and decentralized finance together. Nov 6, 2025, 2:00 p.m.

Aave’s Horizon market, the DeFi protocol’s institutional-grade platform for real-world assets (RWAs), is getting a major boost as Securitize and VanEck bring their tokenized treasury fund, VBILL, to the platform.

STORY CONTINUES BELOW

The integration, powered by Chainlink’s NAVLink oracle technology, represents another leap forward in bridging traditional finance and decentralized finance (DeFi) together.

Since launching in August, Horizon has quickly grown into the fastest-expanding venue for RWAs in DeFi, surpassing $460 million in total market size, according to a press release shared with CoinDesk. The platform's aim is to meet institutional compliance standards while maintaining the transparency and liquidity of onchain finance.

VBILL, launched earlier this year by Securitize and VanEck, is the asset manager’s first tokenized fund.

Now, with VBILL added as eligible collateral, institutions can borrow stablecoins against their VBILL holdings. The integration into Aave Horizon is underpinned by Chainlink’s NAVLink and LlamaGuard NAV oracles, which provide verified, risk-adjusted net asset value (NAV) data to ensure tamper-resistant pricing, the team claims.

Securitize also plans to integrate its Trusted Single Source Oracle (TSSO) system in the future, adding another layer of verification for onchain fund valuation.

“Integrating VanEck’s VBILL with Aave and Chainlink expands access to one of the most trusted forms of onchain collateral and demonstrates how regulated assets can now move fluidly through DeFi,” said Carlos Domingo, the CEO of Securitize, in the press release.

Read more: Securitize, RedStone Pilot ‘Trusted Single Source Oracle’ to Secure Tokenized Fund NAVs

AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.

More For You

Inside Zcash: Encrypted Money at Planetary Scale

Nov 3, 2025

A deep dive into Zcash's zero-knowledge architecture, shielded transaction growth, and its path to becoming encrypted Bitcoin at scale.

What to know:

In 2025, Zcash evolved from niche privacy tech into a functioning encrypted-money network:

Shielded adoption surged, with 20–25% of circulating ZEC now held in encrypted addresses and 30% of transactions involving the shielded pool.The Zashi wallet made shielded transfers the default, pushing privacy from optional to standard practice.Project Tachyon, led by Sean Bowe, aims to boost throughput to thousands of private transactions per second.Zcash surpassed Monero in market share, becoming the largest privacy-focused cryptocurrency by capitalization.View Full Report

More For You

Cango Eyes Strengthening of Bitcoin Mining Operations, Entry Into AI HPC Market

45 minutes ago

The Chinese automotive transaction firm turned bitcoin miner Cango issued an update to its shareholders.

What to know:

Cango said it will prioritize optimizing its bitcoin mining business by improving uptime and improving the energy efficiency of its operations.The company is also pursuing a targeted entry into AI HPC.Cango's board has approved a direct listing on the New York Stock Exchange, which it expects to go live on Nov. 17.Read full story

Journalist

Posted: November 6, 2025

Key Takeaways
What do Algorand’s TD Sequential and RSI suggest about its next move?
Both indicators point to potential bullish relief as ALGO holds key support near $0.152, with RSI rebounding from oversold territory.

How are traders positioning themselves for the possible breakout?
Long accounts dominate at nearly 58% on Binance, reflecting growing optimism that ALGO could reclaim $0.165 and target $0.20.

The TD Sequential indicator has printed two consecutive buy signals on Algorand’s [ALGO] daily chart, fueling optimism for a rebound after a steep decline. 

The Spot Taker CVD shows buy-side dominance, implying that buyers are regaining short-term control. 

Trading near $0.16 at press time, ALGO has defended the lower edge of its descending channel, showing that demand remains active at this level. 

Historically, similar dual confirmations have coincided with local bottoms, often preceding relief rallies. 

As buyer strength increases, momentum could build toward the $0.20 resistance zone, where broader validation of recovery might begin to unfold. 

Can Algorand reclaim strength?
Algorand continued to trade inside a falling channel that has defined its structure since July. Recently, the token rebounded from the lower boundary near $0.152, where buying demand has consistently emerged. 

The RSI sat near 35, reflecting oversold conditions that often precede short-term relief rallies. The technical landscape suggested that a close above $0.165 could confirm a shift in momentum toward $0.20. 

However, losing the $0.152 support would expose the token to another leg lower. Traders are closely watching this zone as the TD Sequential’s buy signal and RSI recovery converge around this crucial technical point.

Source: TradingView

Growing trader optimism
Binance data shows that 57.99% of traders were holding long positions at press time, compared to 42.01% short, pushing the long-to-short ratio to 1.38. 

This jump highlights renewed optimism and rising appetite for leveraged bullish exposure. The timing aligns with the TD Sequential buy setup, reinforcing that traders expect a rebound. 

However, as long positions build, the risk of volatility increases if prices face rejection at upper resistance zones. 

Still, the correlation between growing long positions and the RSI’s gradual uptick suggests improving sentiment that could amplify upward momentum should buying pressure sustain through the coming sessions.

THIS will decide Algorand’s next breakout
The liquidation map on Binance revealed dense clusters between $0.155 and $0.165, marking a key liquidity pocket where leveraged positions are concentrated. 

This zone acts as a pressure point that could trigger either a sharp breakout or a steep pullback, depending on direction. 

If Algorand breaks above $0.165, thin liquidity above could fuel a quick rise toward $0.20. Conversely, a drop below $0.155 might trigger cascading liquidations, dragging the price toward $0.145. 

Hence, this narrow corridor represents a battleground that will likely dictate Algorand’s short-term volatility and trend continuation prospects.

Can bullish signals translate into…?
Algorand’s outlook has improved with the TD Sequential double buy signal, rising long exposure, and RSI recovery, all hinting at potential reversal momentum. 

Maintaining support above $0.152 while clearing $0.165 would confirm this bullish setup and possibly open the door to $0.20. 

However, tight liquidation zones and rising leverage introduce risk if buying pressure weakens.

Sustained accumulation across both Spot and Futures markets will be critical for ALGO to transform this rebound signal into a broader recovery phase.

Is the AI bubble quietly building a fault line that could shake Bitcoin and crypto the way dot-com fever once did?

Summary

The AI bubble is inflating fast, with valuations soaring as speculation outpaces real profits, productivity, and measurable business performance.
Reports reveal heavy AI sector cross-investing and record losses, prompting fears of inflated metrics and government-backed corporate dependence.
Analysts and institutions compare today’s AI boom with the dot-com era, warning that over-financing could trigger a global correction.
Crypto mirrors market anxiety as Bitcoin falls sharply amid fears that an AI-led downturn could deepen risk across digital assets.

The AI bubble and its money loop
Artificial intelligence is fueling a modern gold rush across technology and finance. The boom has reshaped industries from chipmaking to software, sending company valuations to record levels.

Yet many economists and investors warn that excitement may have surpassed the underlying fundamentals. They describe the surge as an “AI bubble,” recalling the late 1990s dot-com era when innovation collided with speculation and markets eventually crashed.

The concern lies in how capital moves through the sector. AI firms are investing heavily in each other’s infrastructure, cloud services, and hardware, creating a circular flow of money that inflates valuations based more on future expectations than on actual profit.

Reports show that OpenAI, one of the central players in this wave, is seeking U.S. federal loan guarantees to support infrastructure projects. 

Chief Financial Officer Sarah Friar confirmed the effort at a Wall Street Journal event, explaining that such guarantees could lower borrowing costs given the vast scale of planned data centers and a $300 billion partnership with Oracle.

Once a nonprofit research lab, OpenAI now operates as a for-profit company that needs tens of billions in annual revenue just to cover computing and energy costs. 

Its model increasingly resembles capital-intensive sectors such as semiconductor manufacturing, where governments often intervene with subsidies or credit support to keep early growth stable.

Skeptics question whether the numbers truly add up. Julian Brigden, co-founder of Macro Intelligence 2 Partners, asked on X why a firm expected to earn “hundreds of billions of dollars” would still require taxpayer guarantees, calling it a possible warning sign of liquidity pressure.

Meanwhile, Michael Burry, the hedge-fund manager known for predicting the 2008 housing collapse, has made a large short bet against the AI sector. 

According to filings with the U.S. Securities and Exchange Commission, his firm Scion Asset Management purchased about $187.6 million in put options on Nvidia and $912 million on Palantir, signaling his view that leading AI firms could face sharp valuation declines.

The mood around these moves has spilled into other speculative markets. Crypto, which often mirrors technology stock behavior, has seen steep losses in recent weeks. 

The total market cap fell from around $4.2 trillion on Oct. 6 to $3.43 trillion a month later, an 18% decline. Bitcoin (BTC) alone dropped nearly 19% in the same period, from $126,000 to roughly $103,000 as of Nov. 6, marking one of its steepest monthly declines in years.

Bitcoin price chart | Source: crypto.news
Let’s understand what is developing beneath the surface, what warning signals are emerging, and how a potential correction in AI markets could spill over into crypto will be crucial in the weeks to come.

Circular cashflows, not real growth
The first real stress test of the AI boom came in early 2025. In January, DeepSeek, a Chinese-developed chatbot, gained unexpected global traction after outperforming its rivals across several benchmarks. 

The surprise sent markets reeling and triggered a sharp correction in leading AI stocks. Nvidia, which had been the centerpiece of the AI surge, fell 17% in a single trading session before recovering 8.8% the following day.

Concerns deepened as actual performance data started emerging later in the year. A Massachusetts Institute of Technology study found that despite $30 to $40 billion in enterprise spending on generative AI, 95% of companies reported no measurable return.

Crypto analyst Hedgie noted that OpenAI lost $13.5 billion on $4.3 billion in revenue during the first half of 2025, meaning ChatGPT continues to operate at a loss nearly every time it is used. 

🦔How catastrophic is it if the AI bubble bursts? Let me break this down.

OpenAI lost $13.5 billion on $4.3 billion in revenue for H1 2025. ChatGPT loses money almost every time you use it. Yet OpenAI targets a $1 trillion IPO based on storytelling, not business fundamentals. An…

— Hedgie (@HedgieMarkets) November 5, 2025

Yet the company is reportedly seeking a $1 trillion IPO, a valuation critics describe as driven more by hype than by business fundamentals.

Market analyst Hedgie described what he called “circular financing,” where companies like Nvidia invest heavily in AI startups that then spend most of that money buying Nvidia hardware. He likened it to giving a lemonade stand $10 to buy $10 worth of lemons and then counting it as $20 of economic growth.

In the first half of 2025, data center spending emerged as one of the largest contributors to U.S. GDP growth, surpassing consumer spending. That growth, however, came largely from corporate expenditure rather than actual revenue generation.

Meanwhile, spending forecasts vary widely, but analysts agree that AI infrastructure spending is set to surge through the decade. Citigroup estimates that major U.S. technology companies could collectively spend more than $2.8 trillion on AI infrastructure by 2029. 

Nvidia’s valuation becomes the clearest symbol of this exuberance. In July 2025, it had become the world’s most valuable company, reaching a $4 trillion market cap, four times its 2023 level. The company alone represented about 7.3% of the S&P 500 index, which also hit record highs during the same period.

Three months later, Nvidia’s valuation surpassed $5 trillion, a figure larger than the GDP of any country except the U.S. and China, based on World Bank data. 

Moreover, AI-related firms have been largely responsible for roughly 80% of all U.S. stock market gains throughout 2025, prompting analysts to question whether the rally stemmed more from concentrated financial exposure than from real productivity growth.

The debate around a potential AI bubble has grown unusually self-aware. Even Sam Altman, CEO of OpenAI and the public face of the current AI boom, admitted in 2025 that an investment bubble is forming.

His acknowledgment carried weight, as OpenAI’s valuation surged from $157 billion in late 2024 to about $500 billion within a year. The company’s rapid growth has come with record infrastructure spending and projections that depend more on sustained investor enthusiasm than on consistent profits.

Several prominent investors have drawn parallels between today’s AI market and earlier speculative eras. Ray Dalio, co-chief investment officer of Bridgewater Associates, said in early 2025 that the scale of AI investment looks “very similar” to what he witnessed during the dot-com boom. 

In October, JPMorgan CEO Jamie Dimon remarked that while AI is a genuine and transformative technology, a large portion of the capital pouring into it may eventually be lost. He warned that markets could be underestimating the chance of a major stock correction within the next two years. 

The Bank of England also cautioned that valuations of leading AI firms, including OpenAI, could prove unsustainable if infrastructure needs exceed what can be financed or managed efficiently. Its report said investors were not sufficiently warned about the risk of a sharp downturn if AI fails to deliver expected performance and profitability.

The International Monetary Fund echoed that concern. Managing director Kristalina Georgieva drew a clear link to the 2001 dot-com collapse, warning that a sudden AI market correction could slow global growth and hit developing economies hardest, especially those dependent on foreign investment and technology imports.

Goldman Sachs, however, offered a more optimistic interpretation. The firm argued that the surge in U.S. technology stocks might be supported by durable profit growth, noting that current valuations remain moderate compared with the late 1990s. 

Meanwhile, Federal Reserve Chair Jerome Powell recently mentioned that AI differs from earlier bubbles because many of the companies driving the current cycle already generate real revenue. He pointed to data center construction and related infrastructure spending as tangible sources of economic activity.

Bitcoin feels the ripple effects
Bitcoin remains under pressure as investor sentiment weakens and economic uncertainty rises. Data from CoinGlass shows the asset has already fallen nearly 11% this quarter, making it the second-worst Q4 since 2020. October alone saw a 3.85% decline, marking the weakest October performance since 2018.

Alex Thorn, Head of Firmwide Research at Galaxy, has lowered his year-end Bitcoin target from $185,000 to $120,000. In a note to clients, he said large holders are offloading coins, corporations are showing reduced interest in holding Bitcoin in their treasuries, and investors are diversifying into other assets.

i’m lowering my BTC bullish EOY target to $120k (prev $185k) 👀

just sent this note to clients

whale distribution, non-BTC investments, treasury company malaise, and other factors contributed to BTC headwinds in 25

(long-term future still bullish, of course) pic.twitter.com/2aj1eoJlno

— Alex Thorn (@intangiblecoins) November 5, 2025

Thorn remains optimistic about Bitcoin’s long-term outlook but expects short-term performance to stay weak due to tightening liquidity and a slowdown in institutional demand.

On-chain data supports that caution. Analyst Maartunn observed that long-term holders currently control about 73.6% of Bitcoin’s total supply, near record highs.

🧵 Bitcoin On-Chain: LTH vs STH — The Truth You Need to Know

Most watch price.
Smart money watches holders.

Here’s what the data says about Long-Term vs Short-Term Holders right now 👇 pic.twitter.com/9v8wgQJBkW

— Maartunn (@JA_Maartun) November 6, 2025

However, in the past month, roughly 363,000 Bitcoins have moved from long-term wallets into short-term hands, indicating active profit-taking as seasoned holders sell and newer investors absorb the coins.

Older wallets are also becoming active again. Over the past year, more than 1.17 million Bitcoins that had been untouched for three to five years have been spent, alongside several hundred thousand from even older addresses.

Maartunn noted that the market now stands at a crossroads. If short-term holders remain calm, prices could stabilize. If they begin selling aggressively, the next leg down could be steeper.

Combined with a global environment that is already under pressure from slowing growth, rising costs, and fears of an AI-driven market correction, crypto investors are facing multiple risks at once. Investors should remain careful, manage exposure sensibly, and never commit more than they can afford to lose.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Fundstrat's Tom Lee has warned that tightening market liquidity and risk headwinds continue to weigh on Bitcoin (CRYPTO: BTC) and other cryptocurrencies.

Liquidity Headwinds Drag On BitcoinSpeaking on CNBC on Wednesday, Lee said Bitcoin remains “highly sensitive to liquidity conditions” and broader market risk sentiment. 

He pointed to a mix of macro headwinds — from the U.S. government shutdown to a hawkish Federal Reserve stance — as catalysts weighing on digital assets.

"The Treasury general account has been building cash," Lee explained. 

"That created a cascade of problems that put pressure on crypto." He added that liquidity stress is a leading factor for Bitcoin's volatility, noting that as funding pressures ease, "headwinds can turn into tailwinds."

Technical Breakdown Confirms Seller Control

BTC Technical Analysis (Source: TradingView)

Bitcoin lost its ascending trendline that supported the entire rally from May, breaking below multiple moving averages. 

The 20-, 50-, and 100-day EMAs now sit overhead between $108,700–$111,700, forming a strong resistance cluster.

The daily candle also shows a clean move into the $100,000–$98,000 demand zone, an area that previously triggered aggressive rebounds. 

If price fails to hold this level, the next major high-volume support sits between $94,000–$92,500, where prior accumulation occurred during the summer rally.

Lee Expects Deleveraging To Take WeeksLee compared the current drawdown to the major deleveraging episodes in 2020 and 2022, when the COVID shock and FTX collapse triggered widespread liquidations. 

He said the Oct.10 deleveraging event was "the biggest in history," and that ripple effects are still being felt.

"The good news is there aren't a lot of bodies floating to the surface," Lee noted. 

"It doesn't feel systematic, but it's going to take some time for confidence to come back." 

He expects the crypto market to stabilize gradually as selling pressure eases and confidence rebuilds over the coming weeks.

Equity Correlation And Investor SentimentLee also linked the weakness in digital assets to profit-taking in equities, particularly the Nasdaq 100, which has rallied for six consecutive months. 

He suggested that both crypto and high-growth stocks are experiencing short-term fatigue after extended gains.

Still, Lee remains constructive on longer-term prospects, citing historical data showing markets that rise six months in a row typically post another 3% average gain in the following month. 

"It's actually a good sign we've been up for six months straight," he said.

Read Next:

Supreme Court Could Blow Up Your 60/40 Portfolio By December — Here’s How To Hedge
Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

You're reading Crypto Long & Short, our weekly newsletter featuring insights, news and analysis for the professional investor. Sign up here to get it in your inbox every Wednesday.

TL;DR:

Trump’s “Bitcoin superpower” remarks fuel a 11.8% TRUMP coin surge.
Whale inflows and bullish charts signal possible targets near $20.
Expansion rumors with Republic.com boost long-term optimism.

The Official Trump coin has reignited market enthusiasm after US President Donald Trump declared his ambition to make the country a “Bitcoin superpower.” The politically charged memecoin surged as traders reacted to Trump’s renewed crypto-friendly stance and speculation over a potential expansion deal.

Trump’s Bitcoin vision fuels a market rally
The Official Trump coin soared 11.8% in 24 hours, trading near $7.88 and outperforming the broader market, which fell 1.3%. The rally followed Trump’s remarks positioning Bitcoin and digital assets as tools to “take pressure off the dollar” and enhance US competitiveness against China. Trading volume surpassed $1 billion on major exchanges, signaling heightened interest.

Technical indicators confirm bullish momentum. Prominent analysts noted that TRUMP’s price broke out of a long-term falling wedge pattern, a classic bullish setup. The coin cleared key resistance at $7.96 and bounced off its 50-day exponential moving average of $7.29. With the RSI around 57 and the MACD showing a positive crossover, market signals point to sustained upward potential, possibly reaching $18–$20 if momentum continues.

Whale accumulation strengthens the trend. On-chain data revealed $91 million in net inflows over three days, while open interest doubled to $351 million. Funding rates turned positive, suggesting long positions now dominate. Yet, analysts warn that centralization concerns remain, as roughly 80% of TRUMP’s supply is reportedly controlled by entities linked to Trump’s inner circle, creating potential volatility risks if profit-taking occurs.

Expansion rumors amplify investor speculation. Reports suggest that Fight Fight Fight LLC, the token’s issuer, is negotiating to acquire Republic.com’s US operations. If realized, the deal could integrate TRUMP into startup fundraising and payment systems, expanding its real-world use cases.

For now, Trump’s pro-Bitcoin narrative and speculation of a “strategic Bitcoin reserve” continue to drive enthusiasm. Holding above $6.64 remains crucial for maintaining bullish sentiment, while breaking $8.07 could open the path toward July’s peak near $11.92.

The discussion surrounding Bitcoin and gold as stores of value has been ongoing for years—and is gaining new relevance amid geopolitical tensions and high inflation.

Since Bitcoin recovered slightly today near $ 103,000, it has raised sentiment across the sector, which has lifted even the QNT price. Now, it has garnered support from key stakeholders, and bullish opinions have emerged, making the Quant price prediction 2025 very interesting. 

When writing, the renewed strength of BTC and rising interest in Quant’s tokenized finance infrastructure have helped QNT reclaim higher levels, setting the stage for a potentially explosive breakout.

QNT Rebounds as Bitcoin Recovers and Market Sentiment ImprovesQNT/USD remained within a compressed range from the beginning of this year, and even July’s rise was brief. From July to November, the price moved from the upper range to the lower range of this pattern, where the recent volatility around the Quant price emerged after the Federal Reserve’s 0.25% rate cut was overshadowed by uncertainty regarding future cuts. 

This uncertainty drove Bitcoin below $100,000 and pushed QNT down to $69 on November 4th. 

However, with Bitcoin recovering above $103,000, optimism returned across the market, allowing QNT price today to rebound to $88, marking a solid 28% recovery. It has slightly retraced to $84.30, with a market cap of $1.02 billion.

This sharp reversal aligns with a long-term ascending trendline visible on the Quant price chart, which has been respected since August 2024, November 2024, April 2025, and now November 2025. Each previous touch on this trendline led to a strong rally, making the current reaction another potentially significant turning point.

Symmetrical Triangle Compression Points to a 200% Breakout SetupThe technical structure surrounding Quant crypto continues to build interest. QNT price has spent months coiling within a symmetrical triangle pattern, creating a tightening range that often precedes major expansions. With the ascending trendline forming a strong foundation, the upper border of the triangle becomes the critical barrier to watch.

If the pattern resolves to the upside, historical behavior suggests a powerful continuation, potentially sending QNT toward $265 before the year ends, which would be a 200% rise from CMP. The longer the compression, the larger the probability of a substantial breakout.

QuantNet Narrative Boosts Confidence in Long-Term ValueBeyond technical signals, fundamental momentum is growing thanks to Quant’s expanding role in tokenized finance. On October 27, 2025, Quant emphasized that the world’s financial system is being rebuilt in real time, with money, assets, and payments rapidly becoming tokenized. 

Yet institutions operate in isolation with different ledgers, networks, and rules  resulting in fragmented liquidity and slow settlement processes.

Here comes the solution from Quant, which aims to solve this bottleneck through QuantNet, described as “the settlement fabric of the digital-asset era.” Rather than replacing existing systems, QuantNet connects them, enabling instant and compliant settlement between banks, tokenized assets, tokenized money, and legacy payment infrastructure.

🚀QuantNet: The Missing Layer in Tokenised Finance

The world’s financial system is being rebuilt in real time.

Money, assets, and payments are all becoming tokenised.

But something crucial is missing, a way to make them work together.

That’s why banks need QuantNet.

— Quant (@quantnetwork) October 27, 2025 This narrative has significantly fueled bullish sentiment, as institutions increasingly seek interoperability solutions that simplify tokenized finance. As adoption grows, the broader QNT price forecast 2025 becomes increasingly compelling.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Haemonetics (HAE - Free Report) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.12 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +13.39%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.01 per share when it actually produced earnings of $1.1, delivering a surprise of +8.91%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Haemonetics, which belongs to the Zacks Medical - Products industry, posted revenues of $327.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.22%. This compares to year-ago revenues of $345.51 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Haemonetics shares have lost about 35% since the beginning of the year versus the S&P 500's gain of 15.6%.

What's Next for Haemonetics?While Haemonetics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Haemonetics was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.28 on $330.9 million in revenues for the coming quarter and $4.80 on $1.3 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Canopy Growth Corporation (CGC - Free Report) , has yet to report results for the quarter ended September 2025. The results are expected to be released on November 7.

This company is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of +88.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Canopy Growth Corporation's revenues are expected to be $52.34 million, up 13.3% from the year-ago quarter.

Enovis (ENOV - Free Report) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +11.94%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.74 per share when it actually produced earnings of $0.79, delivering a surprise of +6.76%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Enovis, which belongs to the Zacks Medical Info Systems industry, posted revenues of $548.91 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.41%. This compares to year-ago revenues of $505.22 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Enovis shares have lost about 28.2% since the beginning of the year versus the S&P 500's gain of 15.6%.

What's Next for Enovis?While Enovis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Enovis was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.86 on $589.06 million in revenues for the coming quarter and $3.13 on $2.25 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Nyxoah SA (NYXH - Free Report) , has yet to report results for the quarter ended September 2025. The results are expected to be released on November 13.

This company is expected to post quarterly loss of $0.61 per share in its upcoming report, which represents a year-over-year change of -10.9%. The consensus EPS estimate for the quarter has been revised 6.1% lower over the last 30 days to the current level.

Nyxoah SA's revenues are expected to be $1.95 million, up 40.5% from the year-ago quarter.

ACI Worldwide (ACIW - Free Report) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +10.10%. A quarter ago, it was expected that this maker of software for electronic payments would post earnings of $0.27 per share when it actually produced earnings of $0.35, delivering a surprise of +29.63%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

ACI Worldwide, which belongs to the Zacks Computer - Software industry, posted revenues of $482.36 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.16%. This compares to year-ago revenues of $451.75 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

ACI Worldwide shares have lost about 7.1% since the beginning of the year versus the S&P 500's gain of 15.6%.

What's Next for ACI Worldwide?While ACI Worldwide has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for ACI Worldwide was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.07 on $473.8 million in revenues for the coming quarter and $2.90 on $1.74 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computer - Software is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Salesforce.com (CRM - Free Report) , has yet to report results for the quarter ended October 2025.

This customer-management software developer is expected to post quarterly earnings of $2.85 per share in its upcoming report, which represents a year-over-year change of +18.3%. The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level.

Salesforce.com's revenues are expected to be $10.26 billion, up 8.7% from the year-ago quarter.

VSee explores collaboration with Philippine Tuberculosis Society and former VP Leni Robredo to expand digital health innovation for Naga City starting with maternal health and primary care SAN JOSE, CALIFORNIA / ACCESS Newswire / November 6, 2025 / VSee Health, Inc. (Nasdaq:VSEE), a leading provider of secure, AI-powered telehealth technology, joined the Philippine Tuberculosis Society and former Philippine Vice President Leni Robredo (currently mayor of Naga City) to discuss opportunities to enhance healthcare delivery in Naga City through digital health innovation. This initial discussion highlighted key healthcare challenges in Naga City, such as prenatal check-up rates-only 44% compared to the Department of Health's 99% target-and the city's efforts to expand access through healthcare caravans (mobile units) and health insurer PhilHealth's YAKAP project, which provides ₱1,700 (USD 29) per qualified patient to local government units delivering full primary care.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, today announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand. The Company is enhancing its capabilities to provide greater value and reliability of product development and manufacturing across the entire development lifecycle for diagnostic innovators worldwide.

With more than 40 years of expertise in assay development, manufacturing, and regulatory compliance, Biomerica is increasingly being approached by biotechnology and diagnostic companies seeking a proven partner to accelerate innovation and scale manufacturing. The Company’s CDMO services are a growing contributor to revenue and represent an opportunity for growth.

“Over the past several years, we have experienced a meaningful increase in interest from both large diagnostic organizations to smaller innovative organizations who are seeking to leverage our specialized development expertise, regulatory compliance track record, and manufacturing capabilities,” said Zack Irani, CEO of Biomerica. “We are now formalizing and expanding these CDMO services, providing clients with end-to-end support from concept through commercial manufacturing.”

Comprehensive Capabilities

Biomerica’s CDMO services enable partners to reduce timelines, streamline production, and ensures reliable, high-quality outcomes in lateral flow, point-of-care diagnostics, ELISA tests, and Multiplex ELISA assays. The services span the entire development lifecycle, including:

Assay Development & Custom Solutions – Custom Lateral Flow Assay (LFA), ELISA and Multiplex ELISA development, companion diagnostics, and 96-well plate coating.Antibody & Reagent Services – HRP antibody conjugation, biotinylation, and colloidal gold antibody conjugation.Recombinant Antibody Development – development of high-quality recombinant antibodies and stable cell lines within weeks.Manufacturing & Assembly – Lateral flow cassette assembly, automated ELISA plate coating, custom lyophilization, and automated reagent filling, labeling, and capping.Supply Chain & Technology Transfer – Global sourcing and qualification of critical raw materials, full technology transfer support, and seamless scale-up into commercial production.
Expanded Website Visibility to Highlight CDMO Services

As part of this initiative, Biomerica has updated its corporate website to prominently feature its CDMO capabilities, making it easier for new partners to understand the Company’s expanded service offering. The updated site showcases service descriptions, and resources to further support collaboration with innovators (https://biomerica.com/contract-development-manufacturing/ )

Positioned for Growth

Backed by ISO 13485 certification, CE-mark expertise, and an FDA registered cGMP manufacturing facility, ensuring regulatory compliance and quality standards at every stage, Biomerica is well-positioned to capture the growing demand for outsourced diagnostic development and production. By providing integrated solutions, Biomerica enables partners to reduce development timelines, de-risk regulatory hurdles, and scale products more efficiently.

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. Biomerica’s expanding CDMO services provide pharmaceutical, biotechnology, and diagnostic companies with trusted solutions for assay development and scalable manufacturing.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s contract product development, compliance and manufacturing, FDA and or international regulatory clearance and compliance for third parties, FDA clearance or possible future clearance of the Company’s own diagnostic tests and/or third-party diagnostic tests and other products, timing of the research, development manufacturing and commercial launch of any of the company’s tests and products or the tests and products of third parties, possible future revenues from contract research, development and manufacturing (CDMO) of tests and products for third-parties, growth in future revenues from the CDMO services provided to third-parties, sale of the company’s own tests and products, international regulatory approval and sales of the company’s tests and products and the products developed by the company for third-parties, the rapidity of research and development of products for third-parties, the company’s ability to manufacture their own tests and products as well as the tests and products of third-parties, and the ability to increase manufacturing capacity to meet future product demands, and competitiveness of the company’s CDMO services pricing. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of research, development and manufacturing of third-party tests; regulatory approvals necessary prior to commercialization of any of the products and tests development and manufactured for third-parties; capacity, resource and other constraints on our suppliers; dependence on our own third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our tests and other products developed and/or manufactured by the company; competition from other similar products and services from competitors that have significantly more financial and other resources available to them; the Company’s ability to comply with current and future regulations in the countries where our products are made and sold; and the Company’s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.

Corporate Contact:

Zack Irani
949-645-2111
[email protected]

Source: Biomerica, Inc.

LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: January 16, 2025 to September 12, 2025

DEADLINE: December 8, 2025

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. aTyr was overwhelmingly positive in its statements to the market about the efficacy of its drug candidate, Efzofitimod. The Company misled investors about the drug’s potential to help patients completely taper the usage of steroids. Based on these facts, aTyr’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

Super Micro Computer (SMCI) stock has declined by 28.4% in under a month, dropping from $58.68 on 10/8/2025 to $42.03 currently. The selloff was driven by disappointing first-quarter fiscal 2026 earnings results released in early November 2025.

CHONGQING, CHINA - JULY 31: In this photo illustration, a person holds a smartphone displaying the logo of Super Micro Computer Inc. (NASDAQ: SMCI), a leading American provider of high-performance server and storage systems, with the company's green oval and red dot logo visible in the background, on July 31, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Getty Images

The company reported revenue of $5 billion for the quarter, which missed expectations by a large margin and and represented a 15% decrease year-over-year. Adjusted earnings per share were also lower than anticipated. The company attributed the mixed numbers to some “design win upgrades” - essentially new customer orders and enhanced product designs - which pushed some expected first-quarter revenue to the second quarter.

What happens next? As it turns out, we think there is a strong possibility of a stock recovery given the historical trends of rebounds following dips and our current Attractive rating of the stock. Buying the dip is a viable approach for quality stocks that have repeatedly bounced back from such downturns.

SMCI stock meets fundamental quality checks. Historically, the stock has averaged (median) a 39% return over one year, and a 67% peak return after experiencing sharp dips (>30% in 30 days). For a little context, SMCI offers high-performance modular server and storage solutions, which include servers, blades, racks, and networking devices targeting enterprise data centers, cloud computing, AI, 5G, and edge computing sectors.

MORE FOR YOU

Historical Median Returns Post Dips

Median returns

Trefis

Historical Dip-Wise Details

SMCI has encountered 10 instances since 1/1/2010 where a dip threshold of -30% within 30 days was met.

67% median peak return within one year of the dip event228 days is the median time to reach the peak return after a dip event-15% median maximum drawdown within one year following the dip eventHistorical Dips

Trefis

Super Micro Computer Passes Basic Financial Quality Checks
Revenue growth, profitability, cash flow, and balance sheet strength should be assessed to minimize the risk of a dip indicating a deteriorating business condition.

SMCI Quality Checks

Trefis

While dip buying can be appealing, it should be assessed carefully from various perspectives. This multi-faceted analysis is precisely how we build the Trefis High Quality (HQ) Portfolio, made up of 30 stocks, which has consistently outperformed its benchmarks encompassing all three — the S&P 500, S&P mid-cap, and Russell 2000 indices. What accounts for this? Collectively, HQ Portfolio stocks have yielded superior returns with lower risk compared to the benchmark index; offering a smoother ride, as shown in HQ Portfolio performance metrics.

The quantum-computing company posted $3.7 million in revenue in the third quarter.

Prestige Consumer Healthcare (PBH - Free Report) came out with quarterly earnings of $1.07 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +10.31%. A quarter ago, it was expected that this medicine distributor would post earnings of $1.01 per share when it actually produced earnings of $0.95, delivering a surprise of -5.94%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Prestige Consumer Healthcare, which belongs to the Zacks Medical - Products industry, posted revenues of $274.11 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.87%. This compares to year-ago revenues of $283.79 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Prestige Consumer Healthcare shares have lost about 23.4% since the beginning of the year versus the S&P 500's gain of 15.6%.

What's Next for Prestige Consumer Healthcare?While Prestige Consumer Healthcare has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Prestige Consumer Healthcare was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.23 on $294.9 million in revenues for the coming quarter and $4.51 on $1.1 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Myomo, Inc. (MYO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 10.

This company is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of -266.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Myomo, Inc.'s revenues are expected to be $9.28 million, up 0.8% from the year-ago quarter.

FAA orders schedule reductions at 40 domestic airports starting Friday due to the government shutdown, prompting United Airlines to offer customer refunds.

November 06, 2025 08:23 ET

 | Source:

ExlService Holdings, Inc.

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, announced that it has been named a Leader in Everest Group’s Property and Casualty (P&C) Insurance BPS PEAK Matrix® Assessment 2025.

Each year, Everest Group presents detailed assessments of P&C business process services (BPS) insurance providers. This year’s report includes 25 companies that are evaluated based on their vision, capabilities and market impact. Researchers determine an organization’s positioning based on Everest Group’s annual request for information process, interactions with leading P&C insurance providers, client reference checks and ongoing analysis of the industry market.

As a Leader in this year’s assessment, EXL was recognized for its consult-to-operate model that integrates insurance domain expertise, data and AI, its leadership in generative AI and autonomous agents and its outcome-driven pricing tied to measurable business results. The Everest Group assessment also highlighted EXL’s deep domain expertise in P&C insurance, its proprietary technology and advanced AI capabilities and its robust partnership ecosystem with leading technology companies.

“EXL is reinforcing its leadership in P&C insurance operations through a consult-to-operate model that fuses domain expertise, data and AI,” said Abhimanyu Awasthi, practice director at Everest Group. “With proprietary IP such as the EXL Insurance LLM, SubroSource™ and XTRAKTO.AI™, and sustained investment in AI, EXL is reshaping claims and underwriting workflows, advancing outcome-based pricing and accelerating ecosystem adoption. These strengths position EXL as a Leader in Everest Group’s P&C Insurance BPS PEAK Matrix®.”

“As the P&C insurance industry accelerates its digital transformation, clients are seeking partners that can translate emerging technologies into measurable business impact,” said Vivek Jetley, president and head of insurance, healthcare and life sciences at EXL. “At EXL, we’re deploying advanced AI agents and automation solutions that help reimagine insurance workflows to transform business outcomes and improve ROI. This recognition from Everest Group validates our leadership in driving real results through innovation.”

To read more about Everest Group’s 2025 Property and Casualty (P&C) Insurance BPS PEAK Matrix® Assessment, visit here.

For more information about EXL’s solutions for the insurance industry, click here.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 63,000 employees spanning six continents. For more information, visit www.exlservice.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

Disclaimer

Licensed extracts taken from Everest Group’s PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

About Everest Group

Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.

Contact
Media
Keith Little
[email protected]

According to recent posts from market commentators, XRP has fallen back under pressure as Bitcoin trades near $103,000 and hovers around the $101,000 support level.

A crypto expert, Coach JV, told followers that seeing XRP trade under $2 would be a “blessing” for disciplined buyers.

Reports have disclosed that XRP gave up the $2.5 level and now faces bears that could push it to new lows below $2.

XRP Drops Near Key Support
Based on numbers from market trackers, the broader crypto market lost about $350 billion in total value between Nov. 3 and 4. XRP was hit hard in that stretch, falling about 14% to roughly $2.2.

Analysts suggested those who missed buying under $2 might get another chance if current weakness continues. Momentum has been driven by Bitcoin’s pullback, and that pressure has been passed down to many altcoins, XRP included.

Bitcoin under $100K? XRP at $2? What a blessing.

Most see disappointment. The disciplined see accumulation.

This is where the patient become wealthy while others chase green candles later, we’ll already be sitting on house money.

GOD, family, and protection of your ecosystem…

— Coach, JV (@Coachjv_) November 4, 2025

Market Moves And Historical Context
Coach JV pointed out that a drop below $2 would wipe as much as 37% off a position opened at the start of August. For example, a $100,000 stake would be worth about $63,000 in that scenario.

Those are headline numbers that grab attention. Yet the message being pushed by some analysts is simple: a downturn can create low-price buying opportunities.

XRPUSD currently trading at $2.32. Chart: TradingView
After the collapse from $3.30 in January 2018, XRP stayed mostly between $0.3 and $0.7 for seven years, until the rally in November 2024 reopened the market for large gains.

Opportunity For The Patient
According to JV, patient accumulation during weak patches is what separates winners from those who chase rallies later. He wrote that when others are chasing green candles, early accumulators are often already sitting on gains.

#XRP – Micro Wick 1 ($10) & Macro Wick 2 ($50):

First of all, imagine waking up after a market bloodbath 😤 and still writing this post with zero fear 😎, because on the higher timeframes, nothing has changed! It’s just your emotions playing games on you.

📖 Step 1: Read This… pic.twitter.com/LrlZf5eMB9

— EGRAG CRYPTO (@egragcrypto) November 5, 2025

This is a common refrain among crypto traders, and it was echoed by other figures in the XRP community. Reports have also recorded that the phase where XRP traded under $1 closed after the 2024 rally, and many now watch the $2 area closely for fresh entries.

Technical Views Remain Bullish On Higher Timeframe
Meanwhile, Egrag Crypto, another analyst focused on XRP, said the long-term chart still looks bullish. He flagged data distortion on Oct. 10 across exchanges like Binance, Bitstamp, and Coinbase, and he identified $1.4 as that date’s low.

That low was noted in his analysis, and he argued that higher-timeframe structure hasn’t been broken. His tone was confident, even as he admitted short-term pain.

Featured image from Unsplash, chart from TradingView

Santiment shared a chart on X on Thursday, showing a rapid acceleration in new wallet creation on the XRP Ledger in what it found was the largest two-day expansion since July, which peaked at about 19,700 wallets.

The United States is positioning itself to become a global leader in Bitcoin and digital assets, as President Trump unveils an ambitious plan to expand the country's crypto infrastructure and regulatory framework. Speaking at the America Business Forum in Miami, Florida, he declared that the federal government would no longer “wage war on crypto.

President Donald Trump wants to transform the U.S into a ‘Bitcoin superpower’. He believes that harnessing the crypto industry is the key to beating China and other countries.

Summary

President Trump vows to make the United States a “Bitcoin superpower” as well as the crypto capital of the world, in hopes of dominating the global crypto industry before China or any other country can.
As of Nov. 6, the U.S holds approximately 326,588 BTC or equal to $33.69 million, making it the largest government to hold BTC compared to China, the U.K and UAE.

Speaking at the two-day America Business Forum in Miami, Florida, President Donald Trump called for business leaders and the wider nation to embrace crypto, particularly Bitcoin. He also emphasized the crypto industry’s role in advancing the U.S economy, particularly by taking pressure off the U.S dollar.

“We’re making the United States the Bitcoin superpower, the crypto capital of the world,” said Trump in Miami, Florida. He also added that the U.S is also the “undisputed leader in artificial intelligence.”

Trump also took the opportunity to bring up growing global competition, as more and more governments have jumped on the crypto bandwagon. He explicitly mentioned China as one of the U.S’ key contenders for the title of “crypto capital of the world.”

“And don’t forget, if we don’t do the crypto properly, China … China wants to do it. They’re starting it, but they want to do it. Other countries want to do it. If we don’t do it properly, it’s a big industry,” warned Trump.

China’s stance on crypto has shifted from hard opposition to somewhat lukewarm after stablecoin adoption rapidly increased worldwide, with U.S dollar-backed tokens leading the charge. In fact, experts have been pushing for China to collaborate with Hong Kong to issue yuan-backed stablecoins to topple the U.S dollar’s dominance over the sector.

Last month, JPMorgan analysts predicted that the rise of stablecoin adoption worldwide could generate around $1.4 trillion in demand for the U.S dollar by 2027.

During his speech, Trump commended his administration for reversing the damage done to the crypto industry by the Biden administration. Financial regulators and officials under the previous Presidential term were notorious for being anti-crypto and worked to criminalize major players in the crypto industry, most notably Binance, Coinbase and Ripple.

“I’ve also signed historic executive orders to end the federal government’s war on crypto. Crypto was under siege. It’s not under siege anymore,” said Trump, referring to his executive orders that called for the creation of a Strategic Bitcoin (BTC) Reserve and a U.S Digital Asset Stockpile.

How much Bitcoin does the U.S hold?
At press time, the U.S remains the largest government entity holding BTC. According to data from Bitcoin Treasuries, the U.S government currently holds around 326,588 BTC or equal to $33.69 billion. This trove mostly comes from seized BTC from criminal violations and forfeitures, representing about 1.55% of the total BTC supply. So far, the U.S has not made any moves to purchase BTC.

China is currently in second-place with its BTC holdings amounting to 190,000 BTC. Like the U.S, China’s BTC holdings were accumulated from seized BTC collected over the years by authorities.

The U.S is home to the largest number of companies that hold Bitcoin | Source: Bitcoin Treasuries
The U.S is also the country with the highest number of BTC-holding entities on the map. As of Nov. 6, there are a total of 123 U.S companies stockpiling BTC. The top three corporate holders of BTC, Strategy, MARA Holdings, and XXI, are all based in the U.S. Meanwhile, Canada only has 43 companies holding BTC and the U.K hosts 23 companies.

Aside from BTC holdings, the U.S is also one of the top countries in terms of cryptocurrency adoption. On the Chainalysis 2025 Global Crypto Adoption Index, the U.S was ranked number two in terms of overall crypto adoption. The country came second place only to India, which ranks first in all categories.

Despite this, the U.S dollar still holds dominance over the stablecoin market, contributing to more than 90% of the total market cap.